Key Takeaways
- Recent studies suggest that the thymus remains important throughout adulthood, impacting longevity and responses to cancer treatment.
- A deep-learning model assessed thymic health from CT scans, revealing strong links to lower mortality and cancer progression risks.
- High thymic health correlates with T cell receptor diversity, which explains why some patients respond better to immunotherapy.
- Chronic inflammation, obesity, and inactivity negatively affect thymic health, highlighting modifiable lifestyle factors.
- The findings prompt a reconsideration of the thymus in adult health, although clinical applications of the imaging method are still years away.
Medicine wrote the thymus off decades ago. Tucked behind your sternum, it does its most important work before you reach puberty, training immune cells and then, almost inevitably, shrinking into a lump of fat. By adulthood, doctors had largely stopped thinking about it. That assumption, it turns out, may have been one of the more consequential oversights in modern medicine.
Two studies published today in Nature, both from the Artificial Intelligence in Medicine program at Mass General Brigham, suggest the thymus remains biologically active and consequential throughout adult life, and that its condition may help predict who will die early, who will develop cancer, and who will respond to immunotherapy.
The first study applied a deep-learning model to routine CT scans from more than 27,000 adults enrolled in the National Lung Screening Trial, assigning each person a “thymic health” score based on the size, shape, and composition of the organ. The results were striking. Over 12 years of follow-up, people with the highest thymic health scores had roughly 50% lower all-cause mortality than those with the lowest, a 63% reduction in cardiovascular death, and a 36% lower chance of developing lung cancer, associations that held up after adjusting for age, sex, smoking history, and existing conditions. A second cohort, the Framingham Heart Study, independently confirmed the cardiovascular link.
The second paper moved to cancer treatment. In a cohort of 3,476 patients receiving immune checkpoint inhibitors for various cancers, high thymic health was associated with a 37% lower risk of disease progression and a 44% lower risk of death.
Those numbers are hard to dismiss. Immunotherapy works by unleashing T cells against tumours, and it has always been poorly understood why some patients respond dramatically and others barely at all. Tumour biology gets most of the attention when oncologists try to predict response, but the immune system doing the actual fighting has received far less scrutiny. The Brigham team found that thymic health correlated with T cell receptor diversity, a measure of how varied and capable the immune repertoire is, lending biological plausibility to the pattern.
Why did doctors assume the thymus was irrelevant in adults?
The thymus visibly shrinks after puberty and gradually fills with fatty tissue, a process called thymic involution. Since T cell production slows dramatically and previous studies relied on small blood-based analyses rather than large population scans, the assumption that the organ was essentially dormant in adults became entrenched in medical thinking. The new studies use CT imaging at population scale in a way that simply hadn’t been done before.
Could measuring thymic health become a routine health screening?
Not yet. The AI model used in these studies was developed and validated on research cohorts, and the authors are explicit that it is not ready for clinical deployment. The next step would be prospective trials testing whether acting on a thymic health score, through lifestyle modification or future interventions, actually changes outcomes.
What lifestyle factors were linked to better thymic health?
The data showed that smoking, obesity, and physical inactivity were all associated with poorer thymic health scores. The reverse, that not smoking, maintaining a healthy weight, and staying active correlate with better scores, is implied but causation has not been established. Whether directly targeting thymic function through drugs or other means is feasible remains an open research question.
“The thymus has been overlooked for decades and may be a missing piece in explaining why people age differently, and why cancer treatments fail in some patients,” said Hugo Aerts, PhD, director of the AIM Program and the corresponding author on both papers. “Our findings suggest thymic health deserves much more attention and may open new avenues for understanding how to protect the immune system as we age.”
The mechanism is, at least in outline, comprehensible. The thymus generates new T cells and diversifies the immune repertoire; as it involutes it produces fewer, leaving the body increasingly reliant on existing T cells that are poorly equipped to handle novel threats. What varies across people is the rate of that decline. Some adults retain considerably more functional thymic tissue than others of the same age, and the new work suggests this variation has measurable consequences, for longevity, for cardiovascular health, for the capacity to mount an effective anti-tumour response. Chronic inflammation, obesity, smoking, and physical inactivity were all associated in the data with worse thymic health scores, pointing toward modifiable contributors.
The caveat is plain: the imaging method is not yet ready for clinical use. These are observational associations, and the studies cannot demonstrate that improving thymic health will improve outcomes.
What they cannot do, however, is be easily ignored. The thymus is not inert in adults. The question now is whether that knowledge can be turned into something actionable, whether lifestyle changes, or eventually pharmacological interventions, might slow the organ’s decline and extend the window of robust immune function.
The answers will take years. But the question itself feels newly urgent. An organ that medicine had largely retired from consideration is, apparently, still very much at work.
DOI: 10.1038/s41586-026-10242-y /
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.